All News

TLM 2023: Primary care clinicians exposed to a FIB4-based risk stratification algorithm reported applying it routinely for patients with elevated LFTs after the introduction.

TLM 2023: Over 15 years, decompensated cirrhosis and OHE notably rose among Medicare beneficiaries with cirrhosis, exceeding 40% and 20% in 2020.

TLM 2023: The simple noninvasive tool may be an alternative to FIB-4, researchers said, and the new data may have implications for NAFLD surveillance.

The predictive algorithm uses FibroScan-captured CAP and LSM data plus 5 clinical variables to identify advanced fibrosis in persons with MASLD.

TLM 2023: The burden of CAD is similar between persons with hepatic steatosis at low and high ASCVD risk, but rate of MACE is higher in the low-risk population.

TLM 2023: Use of rifaximin significantly reduced mean number of OHE episodes as well as hospital contacts, including ED visits and admissions.

TLM 2023: Investigators found that the protective effects of statin therapy against late stage liver disease increased with age older than 51 years.

TLM 2023: Relying solely on a primary diagnosis for overt hepatic encephalopathy underestimates the actual rate, length of stay, and costs of OHE hospitalizations.

TLM 2023: In participants with metabolic dysfunction-associated steatotic liver disease, retatrutide 8 mg and 12 mg resolved steatosis in >85% of subjects.

Should the monovalent COVID-19 vaccine approved for use this respiratory virus season be given universally or to only those at high risk? There are differences of opinion.

The second GLP-1 mimetic-based drug approved for chronic weight management, tirzepatide may outperform semaglutide, the first.

Physician author Terry Brenneman, MD, suggests a key difference between a great clinician and an average one, and it has to do with used car sales. Read more.

President of the Alabama Obesity Society, Dr Jonathan Parker, discusses obesity as a risk factor for hypertension.

Your daily dose of the clinical news you may have missed.

NAFLD, a term coined in the mid-nineteenth century but never an accurate name for the diseases it now stands for, was ready to go, agreed international experts.

The shift in naming for diseases historically known as nonalcoholic fatty liver disease will be top of mind at The Liver Meeting 2023. Get a quick look at why.

Experts wrap up their discussion of emerging chronic kidney disease tests and treatments with key takeaways for providers and patients.

Robert Busch, MD, provides his approach on implementing artificial intelligence (AI) testing for chronic kidney disease and offers success stories of this testing and treatment approach.